Browse the evidence

Hypothalamic inflammation, characterized by microglial activation and increased SOCS3 expression, leads to leptin and insulin resistance in the central nervous system, promoting orexigenic signaling and weight gain.

High-fat, high-calorie diets can cause inflammation in the brain's appetite control center, blunting the 'fullness' signal. Reducing dietary quality and caloric intake can reduce this central inflammation and restore sensitivity to satiety hormones.

Metabolic surgery (specifically Roux-en-Y gastric bypass) yields higher remission rates than adjustable gastric banding, independent of the amount of weight lost.

For obese patients considering surgery, Roux-en-Y gastric bypass offers significantly higher remission rates than adjustable gastric banding, even if the weight loss is similar. This is due to hormonal changes in the gut, not just calorie restriction.

Following unaccustomed eccentric exercise, females exhibit a blunted satellite cell expansion and inflammatory gene expression (Pax7, CCL2) compared to males, suggesting a delayed or reduced myogenic response.

If you are female, your muscle may not expand its satellite cell pool as aggressively as a male's after intense eccentric exercise (like heavy downhill running or heavy eccentrics). This doesn't mean you can't build muscle, but your initial repair signaling might be different. Focus on consistent training and adequate protein intake, as your body may rely on different mechanisms for repair than males.

Exenatide does not demonstrate superior weight loss compared to placebo in adults with craniopharyngioma-related obesity when both groups receive intensive lifestyle interventions.

For adults with obesity caused by brain tumor treatment (craniopharyngioma), adding exenatide to a strict diet and exercise plan does not lead to significantly more weight loss than the diet and exercise alone. The medication may reduce hunger scores, but it does not translate to superior weight loss outcomes in this specific population.

Exenatide reduces hunger scores in adults with craniopharyngioma-related obesity, although this does not translate to significant weight loss.

Exenatide may help reduce the subjective feeling of hunger in patients with craniopharyngioma-related obesity, but this reduction in hunger does not necessarily lead to greater weight loss compared to lifestyle interventions alone.

GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.

GLP-1 medications work partly by changing how your brain processes food cues before you even eat. By activating specific brain regions (DMH), they signal 'stop' based on anticipation, not just stomach fullness. This cognitive effect helps reduce meal size and frequency, contributing to weight loss beyond just slowing digestion.

GLP-2 receptor activation improves intestinal barrier function and reduces systemic low-grade inflammation in obesity, but does not directly reduce appetite or body weight in humans.

GLP-2 receptor agonists (like teduglutide) are not currently recommended for weight loss in humans because they do not reduce appetite or food intake. However, they may help reduce systemic inflammation by improving gut barrier function, which is a key driver of obesity-related complications. This strategy is best used in combination with other weight-loss interventions (like GLP-1 agonists) rather than as a standalone treatment.

Obesity acts as an independent risk factor for chronic kidney disease progression through direct mechanisms (pro-inflammatory adipocytokines, renal hemodynamic alterations causing glomerular hyperfiltration) and indirect mechanisms (hypertension, type 2 diabetes).

Maintain a healthy weight to protect kidney function. Obesity directly stresses the kidneys through hormonal and blood flow changes, leading to protein leakage and reduced filtration. Weight loss interventions can slow this progression.

SGLT2 inhibitors reduce cardiovascular disease risk and mortality in Type 2 Diabetes patients, but are associated with increased risks of urogenital infections, dehydration, hypotension, osteoporotic fractures, and limb amputation.

SGLT2 inhibitors offer significant cardiovascular benefits but require caution in elderly patients and those with kidney disease due to risks of dehydration, hypotension, and infections. Monitor for signs of these side effects.

Acute exposure to moderate terrestrial altitude (2320 m) does not enhance metabolic stress or anabolic hormonal responses compared to normoxia during hypertrophy-oriented resistance training.

If you are training at moderate altitude (around 2300m), do not expect your muscles to grow faster or your hormones to spike more than they would at sea level, provided you are doing the same resistance training routine. The acute stress response is not enhanced by the altitude itself in this context.

Inhibition of HIF1α signaling allows regenerating skeletal muscle myofibers to bypass a neonatal maturation checkpoint, thereby accelerating muscle repair and growth following injury.

This research identifies a biological 'brake' on muscle repair: if HIF1α signaling stays high after an injury, the muscle gets stuck in an immature, small state. Pharmacologically lowering HIF1α (e.g., with PX-478 in mice) or genetically removing it allows the muscle to mature faster and grow larger. For humans, this suggests that strategies to modulate hypoxia signaling or mitochondrial fusion (Mfn2) might accelerate recovery from severe muscle trauma, though no such therapy is currently available for general use.

Short-chain fatty acids (SCFAs) such as acetate and propionate regulate glucose homeostasis primarily by activating the GPCR FFAR2 on enteroendocrine L-cells, stimulating the release of GLP-1, which in turn promotes insulin secretion and improves glucose tolerance.

To leverage the glucose-lowering benefits of short-chain fatty acids, focus on consuming fermentable dietary fibers (like those in oats, legumes, and resistant starches) to feed gut bacteria. These bacteria produce SCFAs (acetate, propionate, butyrate) which activate FFAR2 receptors in your gut. This triggers the release of GLP-1, a hormone that signals your pancreas to release insulin more effectively, thereby improving blood sugar control. This is particularly beneficial if you have insulin resistance or type 2 diabetes.

Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, significantly improves both NASH resolution and fibrosis in patients with stage 2-3 fibrosis.

Resmetirom is a prescription medication for NASH with significant fibrosis that has shown the ability to improve both liver inflammation and scarring in clinical trials. It is not an over-the-counter supplement and requires medical supervision.

Obeticholic acid (OCA) reduces hepatic fibrosis without worsening NASH, but its efficacy is modest and it carries safety concerns leading to FDA rejection.

Obeticholic acid can reduce liver scarring in pre-cirrhotic NASH, but its modest benefits and side effects (itching, liver toxicity) led to FDA rejection, making it a less favorable option.

Pegozafermin, an FGF21 analogue, significantly improves fibrosis and NASH resolution in patients with stage 2-3 fibrosis.

Pegozafermin is an experimental FGF21 analogue that has shown significant improvements in liver scarring and NASH in clinical trials, offering hope for patients with stage 2-3 fibrosis.

GLP-1 receptor agonists (GLP-1 RAs) are dependent on residual beta-cell function and insulin availability, meaning that as Type 2 Diabetes progresses and beta-cell function declines, GLP-1 RAs lose efficacy and patients eventually require insulin therapy.

If you have Type 2 Diabetes, GLP-1 medications (like Ozempic or Trulicity) work by asking your pancreas to make more insulin. If your pancreas is still working well, these drugs are very effective. However, Type 2 Diabetes is progressive, and your pancreas naturally makes less insulin over time. Eventually, these drugs may stop working well enough on their own. At that point, adding insulin is not a failure; it is the necessary next step to keep your blood sugar safe and protect your body from complications.

GLP-1 agonists (e.g., semaglutide, tirzepatide) significantly delay gastric emptying and increase retained gastric contents, thereby increasing the risk of intraoperative pulmonary aspiration during general anesthesia even after standard preoperative fasting.

If you take GLP-1 agonists (like Ozempic or Wegovy) and are having surgery, tell your anesthesiologist. Standard fasting might not be enough to empty your stomach because these drugs slow digestion. Your doctor may use an ultrasound to check your stomach before surgery or adjust your anesthesia plan to prevent aspiration.

Central GIP receptor (GIPR) agonism decreases body weight and food intake in diet-induced obese mice by activating GABAergic neurons in the area postrema, a mechanism that is independent of hypothalamic GIPR signaling.

Newer weight-loss medications that combine GLP-1 and GIP (like tirzepatide) work partly by activating GIP receptors in your brain's satiety centers. This helps reduce food intake. While GIP was once thought to only help with insulin, its role in the brain is now recognized as beneficial for weight loss.

Multi-receptor incretin drugs are associated with an increased risk of adverse events (primarily gastrointestinal) compared to placebo, but do not significantly increase the risk of serious adverse events.

Be aware that multi-receptor incretin drugs commonly cause gastrointestinal side effects like nausea, which may lead to discontinuation for some. However, the risk of serious health events is not significantly higher than placebo. Discuss potential side effects with your doctor and report any severe or persistent symptoms.

Short-term selective dietary fat restriction (30% calorie reduction) decreases dopamine D2/3 receptor binding potential and neural activity in brain reward regions, leading to increased selection of high-fat, high-carbohydrate foods.

If you are on a low-fat diet, you may find yourself craving high-fat, high-carb foods more intensely. This is likely due to changes in your brain's dopamine system, not just hunger. Be aware that this biological shift can make sticking to a low-fat diet harder, even if you feel satiated by the food itself.

For polygenic obesity, precision medicine approaches targeting specific genetic variants or phenotypes have not yet translated into reliable clinical guidance for selecting obesity medications, making early weight loss response the only consistent predictor of long-term efficacy.

Do not rely on genetic testing or complex phenotyping to choose your obesity medication right now, as it does not reliably predict success for common obesity. Instead, use a 'trial and error' approach guided by side effect profiles, comorbidities, and patient preference. The most important indicator of whether a medication will work for you long-term is whether you lose at least 5% of your body weight within the first 12-16 weeks.

Epicardial adipose tissue (EAT) contributes to Heart Failure with Preserved Ejection Fraction (HFpEF) through two distinct mechanisms: mechanical pericardial restraint and local inflammatory/fibrotic secretion.

For patients with HFpEF, managing epicardial fat is crucial. While general weight loss helps, specific interventions like bariatric surgery or Mediterranean-style diets have been shown to reduce EAT volume and improve heart mechanics. Monitoring EAT via imaging can help assess risk and treatment efficacy.

Visceral fat accumulation activates the Renin-Angiotensin-Aldosterone System (RAAS) and Sympathetic Nervous System (SNS), leading to hypertension and sodium retention, independent of dietary salt intake.

High blood pressure in obesity is driven by hormones from belly fat, not just salt. Reducing visceral fat helps normalize these hormones and lower blood pressure.

Obesity increases the risk of various cancers, including breast, endometrial, ovarian, kidney, thyroid, and gastrointestinal cancers, through mechanisms involving chronic inflammation, adipokine secretion, and epigenetic dysregulation.

Obesity increases your risk of several types of cancer, including breast, endometrial, and gastrointestinal cancers. This risk is driven by chronic inflammation and hormones secreted by fat tissue.